Posted by Michael Wonder on 27 Jan 2021
European Medicines Agency accepts GBT’s marketing authorisation application for Oxbryta (voxelotor) for the treatment of haemolytic anemia in sickle cell disease
27 January 2021 - Global Blood Therapeutics today announced that the EMA has completed the validation of GBT’s marketing authorisation application for Oxbryta (voxelotor) tablets and started its standard review process.
GBT is seeking full marketing approval from the EMA for Oxbryta to treat haemolytic anemia in patients with sickle cell disease who are 12 years of age and older.
